GLG Network Survey Tracker: MedTech II

Please complete the form below to request access to the survey data.


GLG interviewed 70 senior executives working at MedTech companies in the US and Europe. This is the second survey following the first iteration published in August 2021.

What will you learn from this survey?

  • Respondents discussed the COVID-19 impact on the market and provided their views on the current regulatory landscape.
  • The survey also gathered insights into the current demand for medical devices and reimbursement mechanisms.
  • Lastly, the research looked into the experts’ views on whether or not organisations started or reprioritised new product development projects to accelerate new products that would take advantage of the opportunities created by the COVID-19 crisis.

Examples of findings:

  • 43% of respondents (up from 37% in 2021) believe MedTech organizations are currently performing better than pre-COVID-19.
  • The majority (60%) believe R&D investment levels in 2022 have returned to pre-COVID-19 levels.
  • 40% of respondents anticipate a revenue increase of 10% or more in 2022 compared to 2021 for the served market.


The GLG Surveys team drafted the questionnaire with the support of GLG Network Member, Timothy DeLapp, former Global Director Physician Relations & Initiatives at Medtronic Plc.

The standard deliverable includes: 

  • 1 x Individual responses (“raw data”) in Excel.
  • 1 x PPT report with aggregated data.
  • Executive summary with key takeaways and highlights from the raw data.


  • Who do you consider to be the top three main players in your market place or market space?
  • Thinking of the impact of COVID crisis environment [2020 & 2021], how do you think medtech organizations in your market place/ market space are currently performing compared to pre-COVID-19 period?
  • Which of the following have major impact on organizations’ in your market place/ market space ability to generate revenue in 2022?
  • From your experience, how was the 2020/2021 investment in R&D affected by COVID-19?
  • In your view, did organizations start or reprioritize new product development projects to accelerate new products that would take advantage of opportunities created by COVID crisis?
  • Looking forward, what are the three most important trends for businesses in your sector?

This survey is available to subscribers of the Healthcare (HC) sector (Limited subscriptions and above). This offer includes the raw data file and a high-level presentation through PowerPoint. Please contact your GLG representative for details on your firm’s access.

Request other available and upcoming Network Surveys within the sector:

  • GLG Tracker: IVF Clinics II ​- New!
    • Second survey to follow the first wave conducted in May 2021. 70 IVF professionals (gynaecologists and senior level professionals at IVF clinics, public and private hospitals/ practices) across the US and Europe discussed the current demand trends and COVID-19 impact on the industry.
    • Questionnaire was drafted by Kristof Kunzmann, former CFO at IVI UK.
  • Liquid Biopsy Testing ​- New! 
    • 70 oncologists across the US and Europe commented on the adoption of liquid biopsy testing and use of various providers such as Guardant, Illumina, Thermo Fisher, Foundation Medicine etc.
    • Questionnaire was drafted by Emmanuel Thomas, MD/PhD Member of Cancer Center Medical Protocol IRB Review and Monitoring Committee (MPRMC).



Please be advised that GLG Network Surveys operate differently than traditional GLG consultations, surveys, teleconferences, etc. and it is advisable that you consult with your firm’s legal and/or compliance department to review your use of the product and the payment for such work under your current subscription.

By downloading this document and/or participating in the Network Survey, you understand and agree that the information and material provided by GLG, including survey results and survey proposal information, is provided for your own insight and informational purposes only. You further acknowledge and agree that this is a Network Survey for multiple GLG clients, and the results will be provided to all GLG clients that agree to participate in the Network Survey and GLG clients that agree to purchase the Survey results in the future. All survey results do not constitute investment advice or a recommendation. In using this Survey, you agree to hold Gerson Lehrman Group and the Survey respondents harmless and free of all liability as a result of your use of this Network Survey, other than liability resulting from the gross negligence or wilful misconduct of the protected party. You otherwise agree to be bound by Gerson Lehrman Group’s Usage Policies in your interactions with Gerson Lehrman Group and your receipt of services. These Survey results are for are for client’s own use and client shall not redistribute, disseminate, publish, or display the same, in whole or in part, to any third parties or publicly without the prior written permission of Gerson Lehrman Group, except explicitly set forth in your agreement with GLG. This survey will be double-blinded to both client and respondent. GLG reserves the right to restrict the number of clients that can pre-commit access. These Network Surveys are priced outside of standard GLG subscriptions but at a substantially reduced price to commissioning a fully proprietary GLG Network Survey. Upon finding these terms acceptable, please send an affirmative confirmation via email, which GLG will file in its records. Once confirmed, please note that the Client’s agreement to purchase the Network Survey is a legally binding and irrevocable commitment. If the survey is not included within your subscription, GLG will invoice Client for the fees due for the Network Survey. Please note that some respondents may not be Network Members, and the Terms and Conditions of Network Membership would not apply to such respondents and detailed records for them will not be available aside from the information that GLG captures in the Network Survey.

Request Access